Amyloid oligomers: A joint experimental/computational perspective on Alzheimer's disease, Parkinson's disease, type II diabetes, and amyotrophic lateral sclerosis
PH Nguyen, A Ramamoorthy, BR Sahoo… - Chemical …, 2021 - ACS Publications
Protein misfolding and aggregation is observed in many amyloidogenic diseases affecting
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …
Synergy between amyloid-β and tau in Alzheimer's disease
Patients with Alzheimer's disease (AD) present with both extracellular amyloid-β (Aβ)
plaques and intracellular tau-containing neurofibrillary tangles in the brain. For many years …
plaques and intracellular tau-containing neurofibrillary tangles in the brain. For many years …
[HTML][HTML] Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases
U Sengupta, R Kayed - Progress in neurobiology, 2022 - Elsevier
Aggregation of specific proteins are histopathological hallmarks of several
neurodegenerative diseases, such as, Amyloid β (Aβ) plaques and tau neurofibrillary …
neurodegenerative diseases, such as, Amyloid β (Aβ) plaques and tau neurofibrillary …
Half a century of amyloids: past, present and future
Amyloid diseases are global epidemics with profound health, social and economic
implications and yet remain without a cure. This dire situation calls for research into the …
implications and yet remain without a cure. This dire situation calls for research into the …
NLRP3 inflammasome activation drives tau pathology
C Ising, C Venegas, S Zhang, H Scheiblich… - Nature, 2019 - nature.com
Alzheimer's disease is characterized by the accumulation of amyloid-beta in plaques,
aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation …
aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation …
Amyloid-beta peptide and tau protein crosstalk in Alzheimer's disease
AR Roda, G Serra-Mir, L Montoliu-Gaya… - Neural regeneration …, 2022 - journals.lww.com
Alzheimer's disease is a neurodegenerative disease that accounts for most of the 50-million
dementia cases worldwide in 2018. A large amount of evidence supports the amyloid …
dementia cases worldwide in 2018. A large amount of evidence supports the amyloid …
The amyloid-β oligomer hypothesis: beginning of the third decade
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …
Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer's disease and frontotemporal dementia
Aging, pathological tau oligomers (TauO), and chronic inflammation in the brain play a
central role in tauopathies, including Alzheimer's disease (AD) and frontotemporal dementia …
central role in tauopathies, including Alzheimer's disease (AD) and frontotemporal dementia …
The role of α-synuclein oligomers in Parkinson's disease
X Du, X Xie, R Liu - International journal of molecular sciences, 2020 - mdpi.com
α-synuclein (α-syn) is a protein associated with the pathogenesis of Parkinson's disease
(PD), the second most common neurodegeneration disease with no effective treatment …
(PD), the second most common neurodegeneration disease with no effective treatment …
Oxidative stress in alzheimer's disease: A review on emergent natural polyphenolic therapeutics
Objectives The aim of this research was to review the literature on Alzheimer's disease (AD)
with a focus on polyphenolics as antioxidant therapeutics. Design This review included a …
with a focus on polyphenolics as antioxidant therapeutics. Design This review included a …